Roivant Sciences Ltd (NAS:ROIVW)
$ 2.75 -0.11 (-3.85%) Market Cap: 0 Enterprise Value: 0 PE Ratio: 0 PB Ratio: 5.42 GF Score: 55/100

Roivant Sciences Ltd Brepocitinib Program Expansion and Batoclimab Update Transcript

Apr 2, 2026 / 12:00 PM GMT


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROIV.OQ - Roivant Sciences Ltd
Roivant Sciences Ltd Brepocitinib Program Expansion and Batoclimab Update
Apr 02, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the representative program expansion and beauty Oakland map update. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Instructions will be given at that time. Please note this call is being recorded.

I would now like to turn the call over to Stephanie Lee. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning, and thanks for joining today's call to review Brepa Sitnib's program expansion and an update on
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot